Hence, PD-L1 expression on CTCs has once more dual potential for the identification of patients likely to respond to PD treatment in the context of liquid biopsies and as therapeutic target to reactivate the immune system towards systemic cancer cells. This evidence concerns the gene CD274 and cancer.